Beautifully Unblemished April Newsletter 2024
Beautifully Unblemished April Newsletter is here, and it's all about…
Tacrolimus 0.1% approved for vitiligo treatment
27 March 2024
Tacrolimus 0.1% approved for vitiligo treatment
The French National Agency for the Safety of Medicines has…
New Expert Recommendations on Pediatric Vitiligo Care
24 March 2024
New Expert Recommendations on Pediatric Vitiligo Care
By the way, have you seen this? The first-ever US…
VStrong Incyte 2023 Inguinity awards winner
7 March 2024
VStrong Incyte 2023 Inguinity awards winner
Wow, what incredible news! The selection committee has awarded the…
Vitiligo and Us Comic Book
8 December 2023
Vitiligo and Us Comic Book
The French Vitiligo Association is delighted to unveil its inaugural…
Doctors’ training on vitiligo in the D.R.C
23 November 2023
Doctors’ training on vitiligo in the D.R.C
The Association Franco-Congolaise du Vitiligo (AFCV), which was created in…
Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3
20 October 2023
Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3
AbbVie recently announced that its phase 2b study investigating upadacitinib (Rinvoq)…
New therapy for vitiligo patients
18 May 2023
New therapy for vitiligo patients
For a long time, vitiligo was considered purely a cosmetic…
Incyte Announces European Commission Approval Of Opzelura® (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
April 20, 2023 at 10:21 AM EDT Opzelura® (ruxolitinib) Cream is…
The first step for a medicinal product for vitiligo has been authorized in Europe
On February 23, 2023, the European Medicines Agency (EMA) published…
